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Background: Women with Human Papilloma Virus (HPV) persistence are characterized by high levels of IL-10 at
cervix. We have determined whether polymorphisms of IL-10 gene promoter might be associated with increased
risk of squamous intraepithelial cervical lesions (SICL) and whether exist significative differences of IL-10 mRNA
expression at cervix and systemic and serum IL-10 protein between SICL cases and non-Cervical Lesions (NCL).
Methods: Peripheral blood samples from SICL (n = 204) and NCL (n = 166) were used to detect IL-10 promoter
polymorphisms at loci -592A/C (rs1800872), -819C/T (rs1800871), -1082A/G (rs1800896), -1352A/G (rs1800893), by
allelic discrimination and to evaluate serum IL-10 protein. Cervical epithelial scrapings from NCL and biopsies from
SICLs were used for HPV-typing and to evaluate IL-10 mRNA expression level. The systemic and local IL-10 mRNA
expression levels were measured by real time-PCR. Genotypic and allelic frequencies of the selected polymorphisms
were analyzed by logistic regression, adjusting by age and HPV-genotype, to determine the association with SICL.
Results: No significant differences were found between genotype frequencies at loci −819, -1082, and −1352.
Individuals carrying at least one copy of risk allele A of polymorphism −592 had a two-fold increased risk of
developing SICL [adjusted odds ratio (OR), 2.02 (95% CI, 1.26-3.25), p = 0.003], compared to NCL. The IL-10 mRNA
expression and serum IL-10 protein, were significantly higher in SICL cases (p < 0.01), being higher in patients
carrying the risk allele A.
Conclusions: The −592 polymorphism is associated with increased risk of SICL and can serve as a marker of
genetic susceptibility to SICL among Mexican women. According to IL-10 levels found in SICL, IL-10 can be relevant
factor for viral persistence and progression disease.
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The majority of women clear HPV infection sponta-
neously by the antiviral immune response, but it has been
suggested that persistence of HPV infection can be asso-
ciated with the development of squamous intraepithelial
cervical lesion (SICL) [1]. The fact that only a small pro-
portion of HPV-infected individuals will eventually de-
velop cancer of the cervix and the long latency period
between primary infections and cancer emergence suggest
that additional factors are involved in the progression.
Other factors, such as genetic susceptibility or alteration
of the immune response, increase the incidence of HPV-
associated lesions [1].
A predominance of the Th2 cytokine profile, in asso-
ciation with a diminished Th1 profile, has been demon-
strated in patients with cervical cancer (CC) [2-4]. This
shift from Th1 to Th2 might be responsible for facilitating
tumor progression by subverting various cellular immune
surveillance mechanisms. An impaired cellular immune
response induced by immune suppressor cytokines, such
as Interleukin (IL)-10 and Transforming Growth Factor
Beta (TGF-β1) has been involved in High Risk HPV (HR-
HPV) persistence and CC development [2,3,5-7].
IL-10 is a Th2 anti-inflammatory cytokine that partici-
pates in the regulation of the immune response at several
levels [8]. The primary T cell source of IL-10 is the T regu-
latory cell and Th1 and Th2 lymphocytes [9]. IL-10 is pro-
duced by activated CD4+ and CD8+ T cells, Epstein–Barr
virus-transformed lymphoblastoid cell lines, fibroblasts
and monocytes. It has potent inhibitory effects on T cell
proliferation, inflammation and production of Th1 cyto-
kines. Other sources of IL-10 include B lymphocytes [10],
myeloid dendritic cells [11], and mast cells [12]. IL-10,
prevents tumor antigen presentation to CD8+ T cells by
suppressing the expression of Major Histocompatibility
Complex (MHC) class I and II antigens [13], inhibits cost-
imulatory activity of antigen-presenting cells by inhibiting
CD3-Z chain expression [7], and down-regulates MHC
class II expression on monocytes [14]. These properties
support the role of IL-10 as a strong immunosuppressive
cytokine. On the other hand, IL-10 overexpression impairs
Th1 cytokine production with an absence of specific T cell
activation in the tumor microenvironment, thus con-
tributing to cancer development [4]. IL-10 mRNA has
been found in a variety of freshly excised human tumors
[15-21], including CC [4,6].
The biological significance of IL-10 production by
tumor cells remains unexplored. Several studies have
shown that the capacity for IL-10 production in indivi-
duals appears to be influenced by genetic makeup [22],
and several groups have proposed IL-10 as a candidate
gene for CC susceptibility [23-25].
Although several studies have reported that IL-10 expres-
sion might be associated with IL-10 gene polymorphisms,few studies have examined the association between the
genotype frequency of IL-10 and the risk for SICL. In this
paper, we investigated whether there is an association be-
tween IL-10 promoter polymorphisms and the risk for
SICL in Mexican women, and furthermore, whether there
is any variation in systemic IL-10 mRNA expression level
and at cervix level, and the protein level in serum, in the
SICL cases with respect NCL.
Materials and methods
Study design
A cross-sectional study was carried out including 204
newly diagnosed SICL cases (aged 18–70 years) recruited
from Centro de Atención para la Salud de la Mujer del
Estado de Morelos in Mexico, between June 2008 and
November 2010. The SICL cases classified as low- and
high-squamous intra-epithelial lesions (L/HSIL) were
evaluated by two pathologists and only the confirmed
ones were included. The whole population was Mexican
Mestizo with a history of three previous generations
being born in Mexico and with a residency period of
> 1 year in the study area (inclusion criteria). Women
without intraepithelial cervical dysplasia or cancer
(n = 166), were selected as controls (aged 19–72 years)
from Centro de Atención para la Salud de la Mujer del
Estado de Morelos in Mexico between January 2008
and November 2010. They had class I or II Papanicolaou
study negative to high-risk HPV infection and had a
normal colposcopy. Also, to eliminate any selection bias,
SICL cases and controls were screened to ensure that
they do not have active infection Sexually Transmitted
Disease (STD) and chronic inflammatory diseases during
sampling, and used as an exclusion criterion.
The selected controls were matched to the cases by age
(±5 years). The present study was approved by the Bioe-
thics and Research Committee, all study subjects signed
an informed consent letter and all investigation was car-
ried out according to the Declaration of Helsinki. Each
subject was interviewed for lifestyle, socio-demographic
and hormonal factors known to be associated with
increased risk of SICL.
Specimens collecting and samples processing
Peripheral blood from all the subjects was collected by
venipuncture, before any medical treatment, in vacutainer
tubes (7 ml) containing EDTA (Becton Dickinson, BD,
Franklin Lakes, NJ, USA) and in serum-separator vacutai-
ner tubes (4 ml). Cervical epithelial scrapings cells and
fresh cells biopsies obtained from women diagnosed with
NCL and SICL, respectively. Peripheral blood mono-
nuclear cells (PBMC) were obtained by Ficoll-hypaque
density gradients (Hystopaque, Sigma Chemical Co). Ge-
nomic DNA was extracted from PBMC using Genomic
DNA Purification Kit (Fermentas Life Sciences, Vilnius,
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sies previously digested with proteinase K. All possible
measures were taken to avoid cross-contamination of
samples during DNA extraction. DNA concentration and
purity was evaluated by Thermo Scientific NanoDropTM
1000 Spectrophotometer (260/280) and the integrity of
the DNA was determined by electrophoresis in agarose
gels at 0.8%.
Total RNA was isolated from PBMC, cervical epithelial
scrapings and biopsies, using the trizol reagent from Invi-
trogen. First-strand complementary (cDNA) synthesis was





for the human housekeeping glyceraldehyde-3-phosphate
dehydrogenase- GAPDH (250 pb) were used to verify
cDNA integrity. For IL-10 gene expression analysis, real-
time PCR amplification was performed by adding 2 μl of
each cDNA sample to a final reaction mixture of 10 μl
containing 5 μl of TaqMan PCR Master Mix for expres-
sion, 0.4 μl probe and 2.6 μl Dnase-free, molecular grade
water. Amplification cycles (performed on a 7900HT Fast
Real-Time PCR System from Applied Biosystems, Foster
City, CA, USA) were: 94°C for 10 minutes, then 40 cycles
at 94°C for one minute, 54°C for one minute, 72°C for one
minute and 30 seconds; followed by 72°C for 15 minutes.
GAPDH and HPRT1 (hypoxanthine phospho-rribosyl
transferase) were used to normalize the amount of IL-10
mRNA present in each sample [26]. For the construction
of the dynamic range curve for the analysis of IL-10 ex-
pression at the systemic level, PBMC was used, stimulated
with phytohemaglutinin for 72 hours, as well as the SiHa
cell line (which constitutively expresses IL-10) for the ana-
lysis of IL-10 expression at the cervix level.
Cervical epithelial scrapings and biopsy specimens were
tested for HPV. Briefly, viral DNA fragments from the
samples were amplified using consensus primers MY09/
MY11 [27]; LIC1/LIC2 [28]; and GP5/GP6 [29]; that
flanking the L1 region of HPV capsid (Table 1). PCR amp-
lification of GAPDH (250 bp) was used as an internal con-
trol for DNA quality. Cell lines expressing HPV 16 (SiHa)
and HPV-18 (HeLa) were used as positive controls, and
deionized H2O as a negative control. All products were
analyzed by electrophoresis in 2% agarose gels. TheTable 1 Consensus primers used for testing HPV
Gene Primer sequence
MYO9/MY11 50-CGT CCM ARR GCA WAC TGA TC-30 and 50-GCM CAG
L1C1/L1C2 50-CGT AAA CGT TTT CCC TAT TTT TTT-30 and 50-TAC CCT A
GP5/GP6 50-TTT GTT ACT GTG GTA GAT ACT AC-30 and 50-GAA AAA TApurified DNA band obtained was sequenced by the Sanger
method. The HPV sequences were analyzed by BLAST.
HPV types were categorized according to phylogenetic
patterns into low and high risk, HPV16 and HPV18.
The collected samples of blood in serum-separator
vacutainer tube were centrifuged to obtain serum and the
IL-10 protein levels were determined using the human
high sensitivity IL-10 ELISA kit (Abcam, Cambridge UK).
All samples were measured in duplicate and the final IL-
10 concentration was calculated as the average of dupli-
cate readings. The results were expressed as picograms
per milliliter (pg/ml).
Genotyping
The Single Nucleotide Polymorphisms (SNPs) were
selected with the following criteria: 1) Validated SNPs for
frequency or for utilization in the HAPmap Project. 2)
SNPs in the promoter region for which scientific evidence
has been published on their potential role in transcrip-
tional regulation of IL-10. For this selection, the Ensemble
program was used, available at the following electronic
page: http://www.ensembl.org/index.html. 3) SNPs in pro-
moter IL-10, located in binding sites of transcription fac-
tors that potentially influence IL-10 transcriptional
activity, reported in the following database: SNPper. URL:
http//snpper.chip.org.
Six SNPs -2025A/G (rs1800892), -1352A/G (rs1800893),
-1082A/G (rs1800896), -819C/T (rs1800871), -657A/G
(rs1800895) and -592A/C (rs1800872) in the proximal pro-
moter region of IL-10, were typed by allelic discrimination
based on the assay of 5'-nuclease by the technology of the
polymerase chain reaction, in combination with TaqMan
fluorogenic probes in the Applied Biosystems 7900HT Fast
Real-Time PCR System with a 384-Well Block Module.
Reactions were performed in 5 μl volumes and contained
25 ng DNA, 1X TaqMan PCR Master Mix for genotyping
(Applied Biosystems, Foster City, CA, USA) and 900 nM of
each probe. Cycling conditions on the ABIprism 7900 HT
(Applied Biosystems, Foster City, CA, USA) were 2 min,
50°C; 10 min, 95°C followed by 40 cycles of 15 sec, 92°C;
and 1 min, 60°C. End-point fluorescence was measured im-
mediately after cycling. All tests were done in duplicate and
the alleles were assigned using SDS 2.1 software (Applied
Biosystems). Quality control for the genotyping results was
achieved with no sample controls, common homozygous





GGW CAT AAY AAT GG-30 57°C 450 bp [27]
AA TAC TAC TCT GTA TTG-30 50°C 250 bp [28]
A ACT GTA AAT CAT ATT C-30 40°C 150 bp [29]
Table 2 General characteristics of the study population
Characteristics SICL cases (204) NCL (166) P value&
Age (y) *
Mean (SD) 36.3 (10.37) 35.8 (11.40) 0.42
Age at first sexual intercourse (y)*
Mean (SD) 18 (3.07) 19.83(3.98) 0.001
Age at menarche (y)*
Mean (SD) 12.79 (1.55) 12.88 (1.42) 0.57
BMI (Kg/m2)*
Mean (SD) 26.02 (4.21) 25.14 (4.37) 0.06∞
Socioeconomic Level (%)+
Low 81.86 21.08 0.001
Medium 18.14 78.92
Parity +
< 3 31 87.3 0.001
>3 69 12.65
Number of lifetime sexual partners +
<3 88.24 81.93 0.12
4 a 9 9.31 16.27
>10 2.45 1.81
History of STD +
No 28.43 52.4 0.001
Other STDs 55.39 36.14
HPV 16.18 11.45
Family planning method +




Other methods 46.08 34.94
HPV genotype+ 0.001
Negative 29.9 38.55
Other genotypes high risk 16.67 22.29
HPV 18 7.84 21.69
HPV 16 41.67 14.46
HPV 16 and 18 3.92 3.01
SICL: Squamous Intraepithelial Cervical Lesion.
NCL: Non-Cervical Lesion.
The results are expressed as means and SD for continuous variables.
Categorical variables are expressed in percentages.
& P value, Kruskall Wallis continuous variables* and Χ2 categorical variables+.
P < 0.05 NCL versus SICL.
∞T test for variables with normal distribution.
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tween duplicate genotypes was greater than 90%; for quality
control of the genotyping, we used a call rate of 0.99 for
SICL and NCL (number of individuals assigned a geno-
type). When the call rate was less than 0.99, the DNA was
reextracted; and new genotyping was done (only 6 samples
required this procedure).
Statistical analysis
Relevant variables between SICL and NCL, using χ2 or
Kruskall Wallis test for categorical and continuous va-
riables were compared, respectively. Hardy-Weinberg
equilibrium was assessed for each SNP using the allelic
frequencies of the control group. A logistic regression
analysis was used to evaluate the association between
SICL and the genotypes in codominant, dominant and
recessive inheritance models, adjusting by potential con-
founders (age and HPV genotype). ORs were obtained
with their respective 95% CI for each one of the geno-
typic variants. The reference variant was the homozy-
gous of the most common variant. We used the
Bonferroni method for correction of multiple compari-
sons. We accepted a probability of α = 0.05 for making
at least one error and compared each SNP by three
models of inheritance; we then divided our probability
error three ways and used the cutoff: α = 0.05/4 = 0.012 =
0.01. The effect of having one or more risk-associated
alleles with SICL was evaluated by multiple logistic regres-
sions. All possible 2-way interactions between SNPs and
between SNPs and IL-10 mRNA expression at the sys-
temic level were tested by adding multiplicative terms in
the multivariate logistic models.
IL-10 mRNA expression at the systemic level and in
the cervix, as well as the analysis of IL-10 protein con-
centration at the serum level, across the groups, were
analyzed using the Wilcoxon Mann–Whitney test. The
mean estimated difference of Expression Relatives Units
between SICL and NCL at the systemic level and in cer-
vix was evaluated by lineal regression analysis adjusting
by age and HPV genotype. To avoid stratification by eth-
nicity that could potentially confound genetic analyses,
we confined our analysis to Mexican Mestizo population
with two previous generations born in Mexico.
The power calculation was evaluated for each of the
analyzed SNPs, taking into account the value of n fixed
for the study and the minor allele frequency for each
SNP in the NCL (P1), with an expected OR of 1.2, 1.5, 2,
2.5 and 3. The established alpha value was 0.05. The P2
calculation was performed using the following formula:
P1*OR/(1-P1) + (P1*OR). The statistic power obtained
for the SNP −592 C/A for OR 1.2, 1.5, 2, 2.5 and 3 was
0.34, 0.75, 0.99, 1, 1; respectively. All analyses were per-
formed using STATA version 9.2 (StataCorp, Collage
Station, TX, EUA) software program for Windows.Results
Socio-demographic and reproductive sexual characteris-
tics of the studied population are presented in Table 2.
SICL cases were, on average, older than NCL, they had
the first sexual intercourse at a younger age, and also, a
higher number of pregnancies (more than 3 pregnan-
cies). There was a significant difference between the
groups regarding the variables: age at first intercourse,
socioeconomic level, number of pregnancies and history
of STD (p = 0.0001). Models by logistic regression,
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association between known reproductive and socio-
demographic factors (first sexual intercourse, multiparity,
socioeconomic level and history of STD) with SICL.
The HPV prevalence in the studied population was 61%.
The most prevalent genotype was HPV-16, followed by
genotypes 18 and 59.
A descriptive analysis of selected polymorphisms was
carried out (Table 3), establishing genotypic and allelic
frequencies for the -592A/C, -819C/T, -1082A/G and
-1352A/G in the SICL and NCL samples. A greater fre-
quency was observed for the A/C genotype of the −592Table 3 Association analysis of SNPs (−592, -819, -1082, -1352




ORa (IC95%) p Value*
Codominant Model
C/C 50(24.5)/66(40) 1
C/A 105(52)/70(42) 2.0(1.21-3.32) 0.007
A/A 49(24)/30(18) 2.07(1.10-3.89) 0.02
Dominant Model
C/C 50(24.5)/66(40) 1
C/A + A/A 154(76)/100(60) 2.02(1.26-3.25) 0.003
Recessive Model
C/C + C/A 155(76)/136(82) 1
A/A 49(24)/30(18) 1.37(0.79-2.39) 0.25
Alleles
C 205(51)/202(60) 1





ORa (IC95%) p Value*
Codominant Model
A/A 125(61.3)/92(55.4) 1
A/G 66(32.3)/62(37.3) 0.95(0.59-1.52) 0.84
G/G 13(6.4/12(7.3) 1.02(0.42-2.44) 0.96
Dominant Model
A/A 125(61.3)/92(55.4) 1
A/G + G/G 79(38.7)/74(44.6) 0.96(0.61-1.50) 0.87
Recessive Model
A/A + A/G 191(93.6)/154(92.7) 1
G/G 13(6.4/12(7.3) 1.04(0.44-2.44) 0.92
Alleles
A 316(77)/246(74) 1
G 92(23)/86(26) 1.01(0.71-1.45) 0.92
p HWE** 0.72
a. Odds ratio adjusted by age and HPV genotype.
** Hardy-Weinberg Equilibrium in controls (NCL).
*p Value < = 0.01 adjusted by Bonferroni.polymorphism among SICL (50.3%) than among NCL
(42%). No significant deviations were observed from
HWE among controls in any of the genotyped SNPs.
Table 3 shows the association analysis of the SNPs
selected of IL-10 promoter region and the risk of SICL
with ORs estimated through conditional logistic regres-
sion and adjusted by age and HPV genotype. Only C/A
genotype of the −592 polymorphism had a significant as-
sociation with an OR of 2.0 (95% CI, 1.21-3.32), p =
0.007 for the codominant model, confirmed in the dom-
inant model A/C + A/A with an OR of 2.0 (95% CI,




ORa (IC95%) p Value*
Codominant Model
C/C 64(31.4)/57(34.3) 1
C/T 94(46)/75(45.2) 1.16(0.71-1.92) 0.53
T/T 46(22.6)/34(20.5) 1.15(0.62-2.12) 0.64
Dominant Model
C/C 64(31.4)/57(34.3) 1
C/T + T/T 140(68.5)/109(65.7) 1.16(0.73-1.84) 0.51
Recessive Model
C/C + C/T 158(77.4)/132(79.5) 1
T/T 46(22.6)/34(20.5) 1.05(0.61-1.81) 0.84
Alleles
C 222(54)/189(57) 1





ORa (IC95%) p Value*
Codominant Model
G/G 130(63.72)/102(61.44) 1
G/A 64(31.37)/53(31.94) 1.28(0.78-2.07) 0.31
A/A 10(4.9)/11(6.62) 0.85(0.33-2.22) 0.75
Dominant Model
G/G 130(63.72)/102(61.44) 1
G/A + A/A 74(36.27)/64(38.56) 1.20(0.76-1.90) 0.42
Recessive Model
G/G + G/A 194(95)/155(93.38) 1
A/A 10(4.9)/11(6.62) 0.78(0.30-1.99) 0.6
Alleles
G 324(79)/257(77) 1
A 84(21)/75(23) 1.08(0.74-1.58) 0.65
p HWE** 0.26
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1.32 (95% CI, 0.97-1.81), p = 0.07. The other three SNPs
showed no significant differences in any of the tested
genetic models. The multiple models adjusted for age
and HPV genotype did not lead to considerable changes
in any of the results. When we performed the asso-
ciation analysis of SNP −592 C/A in the promoter region
of the IL-10 gene with HPV infection, no statistically sig-
nificant association was found for any of the models
analyzed (data no show).
In order to explore whether the SNPs could act to-
gether to increase SICL risk, the allele load and tested
the effect on risk for SICL were calculated (Table 4). We
found that having one or more risk alleles had a statisti-
cally significant association with SICL, compared with
having no risk alleles; p for trend = 0.014.
IL-10 mRNA expression levels normalized to HPRT1
mRNA and GAPDH mRNA at the systemic level and in
cervix of SICL and NCL patients are shown in Figure 1.
The median levels of IL-10 mRNA relative to GAPDH
and HPRT1 at the systemic level, were higher in patients
with SICL than NCL and the difference was statistically
significant (p < 0.01). IL-10 mRNA expression levels,
normalized to GAPDH and HPRT1 in cervix, were
higher in SICL compared to NCL, at the systemic level,
p < 0.01 (Figure 1). In assessing the association between
IL-10 mRNA expression levels at the systemic level and
in cervix with SICL, the mean estimated difference of
Expression Relative Units between SICL and NCL was
0.13 (95% CI, 0.09-0.18), p = 0.001 at the systemic level
and 0.52 Expression Relative Units (95% CI, 0.44-0.59),
p = 0.001 at the cervix level. Average IL-10 protein levels
in serum were higher in SICL (2.06 pg/ml) compared to
NCL (Figure 2). The mean estimated difference of IL-10
protein in serum, between SICL and NCL, was 1.86 pg/ml.
When we evaluated the interaction between each of
the SNPs: -592, -819, -1082 and −1352, and IL-10 mRNA
expression at the systemic level, as well as the SNP-SNP
interaction, no statistically significant interaction was
found (data not shown).Table 4 Risk allele load and risk for Squamous
Intraepithelial Cervical Lesions (SICL)
Number of alleles
associated with SICL
n ORa. CI 95% P Value*
Total SICL NCL
0 372 174 198 1 -
1 280 127 153 1.07 0.78-1.47 0.66
2 38 17 21 1.17 0.58-2.33 0.65
≥3 50 14 36 2.58 1.33-5.00 0.005
Trend p value 0.014
n = Number of alleles.
a. OR adjusted by age and HPV genotype.
*p < 0.05.Discussion
The most prevalent HPV genotype in the analyzed popu-
lation was 16, similar to other studies previously
reported in Mexican population [30,31]. Persistent HPV
infection, along with environmental and genetic factors
such as IL-10, predisposes individuals to SICL and sub-
sequent progression to cancer [2-4,6,32].
Previously, Hobbs et al., described a C to A exchange
in the IL-10 promoter located 592 bp upstream from the
transcription start site, which is located between putative
consensus binding sequences for Sp1 (GGGGCGG), and
a sequence with similarity to that recognized by mem-
bers of the ETS family proteins (AGGAA). This −592
polymorphism is present in the promoter in a region
with negative enhancer activity and is associated with
loss of this activity [33]. Steinke et al., were the first ones
that demonstrated that the C to A nucleotide exchange
results in increased IL-10 gene promoter activity, sup-
porting its role as a repressor element of the gene C
variant [34]. Previous work from our group discovered
that HPV-16 E6 and E7 oncoproteins binds to Sp1 tran-
scription factor in the TGFß1 promoter and up regulates
gene expression, through a GGGGCGG consensus se-
quence located at −180 to −172 of the TGFß1 human
gene. Taken all together with the results of this paper,
support the hypothesis that HPV-16 E6 and E7 oncopro-
teins may up regulate IL-10 gene expression [35].
This SNP has been linked with increased severity of a
number of autoimmune diseases [36-39], and is asso-
ciated with changes in tumorigenesis and transplantation
tolerance [40], and rapid progression to AIDS in indivi-
duals infected with HIV [41,42]. The current study has
shown that individuals homozygous for the A-allele of
the IL-10 -592 polymorphism are at two times greater
odds of having SICL [OR 2.07, (95% CI, 1.10-3.89), p =
0.02], as compared to NCL. A previous study carried out
in 311 patients with cervical intraepithelial neoplasia
(CIN), 695 cervical cancer patients, 115 family-based
patients and 586 unrelated controls, in Caucasian popu-
lation, revealed the same association, an increased risk
for CIN (II–III) (OR 1.44 [1.06–1.97]) and squamous cell
carcinoma of the cervix (OR 1.35 [1.04–1.75]) for indivi-
duals heterozygous for the A-allele of the IL-10 -592
polymorphism [25].
With respect to IL-10 mRNA expression at the sys-
temic and cervix levels in patients with SICL and NCL,
we also found that the level of IL-10 mRNA relative to
GAPDH and HPRT1 in SICL was significantly higher
than in NCL, at the systemic level. It has been shown
that PBMC from patients with both SICL and CC pro-
duce higher levels of IL-10 following mitogenic stimula-
tion, compared with control groups [2,7]. In addition, it
has been shown that tumors can induce IL-10 produc-
tion by PBMC [18,43]. Women with HPV infection have
Figure 1 IL-10 mRNA levels normalized to GAPDH and HPRT1 at the systemic level and in cervix, in NCL and SICL. The levels were
higher in SICL compared to NCL, at the systemic level and in cervix, p < 0.0001.
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T cells than healthy women, at the systemic level [44].
We also found that the level of IL-10 mRNA relative
to GAPDH and HPRT1 in SICL was significantly higher
than in NCL, at the cervix level. However, here we
showed that IL-10 mRNA was undetectable in some
cases with cervix without HPV infection, suggesting that
normal cervical epithelium does not produce IL-10,
similar findings had been found previously [4,5]. Abnor-
mal IL-10 production at the cervix level has already been
reported in patients with SICL and CC [6,45]. In CC, we
report a high correlation between IL-10 immunostaining
and the level of IL-10 mRNA expression in cervical bi-
opsies, where there is a Th2/Th3 cytokine pattern ex-
pression, suggesting that HPV infection induces the
transcription of immunosuppressive cytokines, IL-10
and TGF-ß, as a means to evade the host immune sys-
tem [4,6,35].Figure 2 IL-10 protein serum levels in women with SICL versus NCL. TIn women with SICL, significant differences of the
levels of IL-10 protein in serum were found between
groups, with virtually undetectable serum protein in
NCL women. The SICL presence, as well as the progres-
sion to CC has been associated with increased serum
levels of IL-10 [6,44]. The level of IL-10 mRNA expres-
sion reported here, at the systemic level and in cervix,
and protein level in serum are higher in SICL cases; this
confirms our previous finding [6].
Conclusions
We showed that individuals who are carriers of hetero-
zygous IL-10 -592 C/A polymorphism had a two-fold
increased risk of developing SICL (OR of 2.0 (95% CI,
1.21-3.32), p = 0.007, when compared to NCL, and to
carry two copies of allele A confers two-fold increased
risk of developing SICL (OR of 2.0 (95% CI, 1.10-3.89),
p = 0.02. The SNP −592 C/A of the IL-10 promoterhe levels were higher in SICL compared to NCL, p < 0.0001.
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http://www.infectagentscancer.com/content/7/1/32could be a risk factor for the development of HPV lesion
in Mexican women, potentially associated with the pro-
duction of high levels of IL-10 at systemic and cervix
levels, which favors viral persistence and SICL develop-
ment. Our study has several strengths: first, the cases
studied here were precancerous lesions, where it has
been demonstrated that IL-10 is responsible for the pro-
found immune response alteration in HPV SICL [2,6].
Additionally, we previously demonstrate that there is a
reduction of T-cell CD3-Z in patients with SICL, asso-
ciated with IL-10 expression [7]. Second, the evaluation
of IL-10 concentration was carried out in the systemic
circulation and at the cervix level. Here, we demon-
strated that there is a significant difference in the IL-10
levels in both sites (systemic and cervix) in SICL cases
to compared with NCL. Therefore, it seems to be that
the presence of IL-10 is an important factor in progres-
sively impaired immune responses against HPV, allowing
viral persistence and SICL development. Third, the −592
polymorphism associated with increased risk of SICL,
can serve as a marker of genetic susceptibility to SICL
among Mexican women and be considered as a candi-
date gene for genetic susceptibility devices that permit
to identify women with high predisposition for the de-
velopment of premalignant lesions in cervix that may
become cases of cervical cancer if not are detected early.
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